118 related articles for article (PubMed ID: 16528611)
1. An analysis of unclassified missense substitutions in human BRCA1.
Tavtigian SV; Samollow PB; de Silva D; Thomas A
Fam Cancer; 2006; 5(1):77-88. PubMed ID: 16528611
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
Tavtigian SV; Deffenbaugh AM; Yin L; Judkins T; Scholl T; Samollow PB; de Silva D; Zharkikh A; Thomas A
J Med Genet; 2006 Apr; 43(4):295-305. PubMed ID: 16014699
[TBL] [Abstract][Full Text] [Related]
3. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.
Tavtigian SV; Byrnes GB; Goldgar DE; Thomas A
Hum Mutat; 2008 Nov; 29(11):1342-54. PubMed ID: 18951461
[TBL] [Abstract][Full Text] [Related]
4. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
Abkevich V; Zharkikh A; Deffenbaugh AM; Frank D; Chen Y; Shattuck D; Skolnick MH; Gutin A; Tavtigian SV
J Med Genet; 2004 Jul; 41(7):492-507. PubMed ID: 15235020
[TBL] [Abstract][Full Text] [Related]
5. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
Akbari MR; Zhang S; Fan I; Royer R; Li S; Risch H; McLaughlin J; Rosen B; Sun P; Narod SA
J Med Genet; 2011 Nov; 48(11):783-6. PubMed ID: 21965345
[TBL] [Abstract][Full Text] [Related]
7. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
[TBL] [Abstract][Full Text] [Related]
8. Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants.
Vallée MP; Di Sera TL; Nix DA; Paquette AM; Parsons MT; Bell R; Hoffman A; Hogervorst FB; Goldgar DE; Spurdle AB; Tavtigian SV
Hum Mutat; 2016 Jul; 37(7):627-39. PubMed ID: 26913838
[TBL] [Abstract][Full Text] [Related]
9. Characterization of common BRCA1 and BRCA2 variants.
Deffenbaugh AM; Frank TS; Hoffman M; Cannon-Albright L; Neuhausen SL
Genet Test; 2002; 6(2):119-21. PubMed ID: 12215251
[TBL] [Abstract][Full Text] [Related]
10. In silico analysis of missense substitutions using sequence-alignment based methods.
Tavtigian SV; Greenblatt MS; Lesueur F; Byrnes GB;
Hum Mutat; 2008 Nov; 29(11):1327-36. PubMed ID: 18951440
[TBL] [Abstract][Full Text] [Related]
11. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Meyer P; Voigtlaender T; Bartram CR; Klaes R
Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
[TBL] [Abstract][Full Text] [Related]
12. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.
Walker LC; Whiley PJ; Couch FJ; Farrugia DJ; Healey S; Eccles DM; Lin F; Butler SA; Goff SA; Thompson BA; Lakhani SR; Da Silva LM; ; Tavtigian SV; Goldgar DE; Brown MA; Spurdle AB
Hum Mutat; 2010 Jun; 31(6):E1484-505. PubMed ID: 20513136
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
14. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
[TBL] [Abstract][Full Text] [Related]
15. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
16. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
17. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.
Zhi X; Szabo C; Chopin S; Suter N; Wang QS; Ostrander EA; Sinilnikova OM; Lenoir GM; Goldgar D; Shi YR
Hum Mutat; 2002 Dec; 20(6):474. PubMed ID: 12442274
[TBL] [Abstract][Full Text] [Related]
19. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.
Mathe E; Olivier M; Kato S; Ishioka C; Hainaut P; Tavtigian SV
Nucleic Acids Res; 2006; 34(5):1317-25. PubMed ID: 16522644
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
